NCT05402722

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

A Phase II Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Beijing 302 Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer.

Conditions

• TNBC - Triple-Negative Breast Cancer

Interventions

Type	Name	Description
DRUG	Eribulin	Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
DRUG	anti-PD-1 antibody	Sintilimab Injection，Intravenous infusion，200mg，3-week cycle

Timeline

• Start date: 2022-01-01
• Primary completion: 2022-12-31
• Completion: 2023-06-30
• First posted: 2022-06-02
• Last updated: 2022-06-02

Locations

1 site across 1 country: China